钠-葡萄糖协同转运蛋白2抑制剂对心血管系统影响的研究进展  

Research Progress of Sodium-Glucose Transporter 2 Inhibitors' Effects on Cardiovascular System

作　　者：王志国[1,2] 徐书杭[3] 陈可洋[2] 

机构地区：[1]南京中医药大学附属中西医结合医院江苏省中医药研究院检验科,合肥230032 [2]安徽医科大学公共卫生学院,合肥230032 [3]南京中医药大学附属中西医结合医院江苏省中医药研究院内分泌科,南京210028

出　　处：《医学综述》2017年第7期1263-1267,共5页Medical Recapitulate

基　　金：江苏省科技创新与成果转化(科技服务平台)专项引导基金项目(BM2012064);安徽省自然科学基金面上项目(1508085MH162)

摘　　要：钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一类新型的抗高血糖药物,该药通过抑制肾小管上皮细胞SGLT2的功能以减少尿中葡萄糖的重吸收,从而达到降低血糖的目的。该药除了降血糖,还具有降低血压、体质量及尿酸水平,改善血脂异常等心血管危险因素的作用,对心血管系统有较好的保护作用,且不良反应小、安全可靠。该类药物在国外上市以来受到广泛关注,随着对药物研究的深入,其作用机制及不良反应也越来越明确,应用也将越来越广泛。Sodium-glucose cotransporters 2 （SGLT2） inhibitors are a new class of antidiabetic agents. By inhibiting thefunction of SGLT2 in renal tubular epithelial cells, the drugs can reduce the re-absorption of glucose in urine, thereby reac-hing the hypoglycemic goal. In addition to the hypoglycemic effect, the drug can also reduce the body weight, blood pressureand uric acid, and improve dyslipidemia and other cardiovascular risk factors, presenting a good protective effect on the car-diovascular system, with less adverse effect and good safety and reliability. Such drugs are widely concerned since marketingin oversea market. With the further study on these agents, the mechanism and adverse effects are getting clearer, and theapplication will be more extensive.

关 键 词：2型糖尿病 钠-葡萄糖协同转运蛋白1 钠-葡萄糖协同转运蛋白2 钠-葡萄糖协同转运蛋白2抑制剂 

分 类 号：R587.1[医药卫生—内分泌]